Dr. Eng on the Role of Adjuvant Chemotherapy in CRC

Video

In Partnership With:

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology, co-leader, Gastrointestinal (GI) Cancer Research Program, professor of medicine (hematology and oncology), co-director, GI Oncology, vice chair, SWOG GI Committee, and director, VICC Young Adult Cancers Initiative, Vanderbilt-Ingram Cancer Center, discusses the role of adjuvant chemotherapy in colorectal cancer (CRC).

Adjuvant chemotherapy provides patients with a reduced risk of disease recurrence, Eng explains.

Historically, adjuvant chemotherapy was given to patients with stage III, lymph node–positive disease following colon resection, explains Eng. Patients with stage II disease may also be eligible to receive adjuvant chemotherapy. Ultimately, that decision should be based on a discussion with the patient.

Primarily, patients with colon cancer are candidates for adjuvant chemotherapy vs those with rectal carcinoma, Eng says.

Ongoing research efforts within the rectal carcinoma paradigm are evaluating moving available treatment options to the neoadjuvant setting, concludes Eng.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center